Sanofi partners with Recludix to develop oral STAT6 inhibitorSTAT6 inhibitor

20 Jul 2023
·
Deals
firstwordpharma.com
License out/inPhase 2
Sanofi signed a strategic collaboration with Recludix Pharma to develop oral small-molecule STAT6 inhibitorsSTAT6 inhibitors for patients with immunological and inflammatory diseases, the latter company said Thursday. The deal represents the second early-stage agreement for Sanofi this week, having unveiled a partnership on Monday with Scribe Therapeutics.
Under the latest collaboration, Sanofi will have global rights to small-molecule STAT6 inhibitorsSTAT6 inhibitors, with Recludix advancing them from preclinical research and development through to the start of Phase II studies. The French drugmaker will subsequently assume development and commercialisation responsibilities, with Recludix having an option to participate in US profit/loss share.
Recludix noted that inhibiting STAT6 - a key nodal transcription factor that selectively mediates downstream signalling of IL-4 and IL-13 – offers the potential to treat patients with multiple Type 2 inflammatory dermatological and respiratory diseases. "Recludix's approach to targeting STAT6 has significant potential…especially where a precisely tailored oral therapy could best fit within the patient's needs at various stages of disease," remarked Frank Nestle, Sanofi's global head of research.
As part of the agreement, Sanofi will make near-term payments of $125 million, with Recludix eligible for more than $1.2 billion in potential milestones, as well as up to double-digit sales royalties.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.